Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

In the CodeBreaK 200 phase III, open-label trial, sotorasib significantly improved efficacy versus docetaxel in previously treated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) for global health status, physical functioning, dyspnea, and cough favore...

Full description

Saved in:
Bibliographic Details
Main Authors: David Waterhouse, Sacha I. Rothschild, Christophe Dooms, B. Mennecier, Farastuk Bozorgmehr, Margarita Majem, Michel H. van den Heuvel, Helena Linardou, Byoung Chul Cho, Rachel Roberts‐Thomson, Kentaro Tanaka, Normand Blais, Gustavo Schvartsman, Karin Holmskov Hansen, Izabela Chmielewska, Martin Förster, Christina Giannopoulou, Björn Stollenwerk, Cynthia C. Obiozor, Yang Wang, Silvia Novello
Format: Artigo
Language:English
Published: 2024
Online Access:https://doi.org/10.1016/j.lungcan.2024.107921
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1016/j.lungcan.2024.107921

Similar Items